Senger Tilo, Schädlich Lysann, Gissmann Lutz, Müller Martin
Department of Genome Modifications and Carcinogenesis, German Cancer Research Centre, D-69120 Heidelberg, Germany.
Virology. 2009 Jun 5;388(2):344-53. doi: 10.1016/j.virol.2009.04.004. Epub 2009 May 1.
Human papillomavirus (HPV) L1 self-assembles into virus-like particles (VLPs), which are the basis for the two commercially available prophylactic vaccines. For one of them (Cervarix) HPV 16 and 18 VLPs are being produced in insect cells using the baculovirus expression system. However, due to low yield, production of VLPs remains challenging for certain other PV types. Here we report that employment of a modified baculovirus-based (MultiBac) expression system (Berger, I., Fitzgerald, D. J., and Richmond, T. J. (2004). Baculovirus expression system for heterologous multiprotein complexes. Nat. Biotechnol. 22(12), 1583-7) permits substantially improved VLP production of several PV types up to 40-fold. Highest VLP yields were achieved when two copies of the L1 gene were expressed from independently controlled cassettes. We have evaluated the production of HPV 57 L1 VLPs by the MultiBac system in more detail. Whereas the level of the HPV 57 L1 protein was only slightly increased in comparison to the standard protocol we monitored a strongly enhanced yield of HPV 57 VLPs. Our results imply that a critical concentration of L1 within the producer cell is required for efficient VLPs assembly. We show evidence that in addition a dominant negative factor in conventionally produced recombinant baculoviruses contributes to differences in VLP yield. This phenomenon might be attributable to the absence of the viral cysteine protease V-CATH in the modified baculovirus system. We anticipate that use of the MultiBac expression system will facilitate capsid production for papillomaviruses and thereby enable the generation of vaccines against infections by many of the as yet untargeted HPV types.
人乳头瘤病毒(HPV)L1能自组装成病毒样颗粒(VLP),这是两种市售预防性疫苗的基础。其中一种疫苗(希瑞适)的HPV 16和18型VLP是利用杆状病毒表达系统在昆虫细胞中生产的。然而,由于产量低,对于某些其他HPV类型,VLP的生产仍然具有挑战性。在此我们报告,采用一种改良的基于杆状病毒的(多杆状病毒)表达系统(伯杰,I.,菲茨杰拉德,D. J.,和里士满,T. J.(2004年)。用于异源多蛋白复合物的杆状病毒表达系统。《自然生物技术》22(12),1583 - 7)可使几种HPV类型的VLP产量大幅提高,最高可达40倍。当从独立控制的盒式结构中表达两份L1基因时,可实现最高的VLP产量。我们更详细地评估了多杆状病毒系统对HPV 57 L1 VLP的生产情况。与标准方案相比,HPV 57 L1蛋白水平仅略有增加,但我们监测到HPV 57 VLP的产量大幅提高。我们的结果表明,生产细胞内L1的临界浓度是高效组装VLP所必需的。我们有证据表明,传统生产的重组杆状病毒中存在的一种显性负因子也导致了VLP产量的差异。这种现象可能归因于改良杆状病毒系统中缺乏病毒半胱氨酸蛋白酶V - CATH。我们预计,使用多杆状病毒表达系统将有助于乳头瘤病毒衣壳的生产,从而能够生产针对许多尚未有针对性疫苗的HPV类型感染的疫苗。